How Can We Help?
Skip to content
Researcher looking at a book
Access ADME Logo

ADME 101™

ADME 101™ is a new mini-webinar series of presentations by our scientists which highlight relevant aspects of ADME properties of drugs, assays we perform, topical regulatory considerations, overviews of related components of an IND, and more.

This series of educational short videos is constantly growing to represent a comprehensive resource for researchers and industry professionals to navigate ADME, DMPK, and DDI within the complex landscape of drug development. As we continue to update and add to our repository of resources, we welcome questions and requests for topics our experts may address in future presentations. Please use our online forms to request a topic or get in touch with our team.



Eliminating Problems in Drug Development: Understanding the Role of Drug Metabolism

Presenter: Andrew G. Taylor, Ph.D., Manager of Technical Support for Services at SEKISUI XenoTech Abstract: This talk will discuss processes for the metabolism of a drug,...

SAFETY FIRST: Assessing drugs early can preclude regulatory and health issues

Authors: Madison Esely-Kohlman, Dr. Maciej Czerwinski, Dr. Pallavi Limaye, Dr. Brian Ogilvie A Guide to When & Why to Evaluate ADME/PK & Drug-Drug Interactions With...

ADME 101: Drug Metabolism Studies – Metabolic Stability

Metabolic stability influences the oral bioavailability and plasma half-life of a compound. Metabolic stability assays measure intrinsic clearance and determine the extent to which a drug will be metabolized. This study can be conducted in a variety of test systems, which is why it may also be referred to as a hepatocyte stability study, microsomal stability study...

ADME 101: Model-Based Approaches to DDI Risk Prediction – Navigating the Transition from In Vitro Data to In Silico Modeling

This informative ADME 101 discusses In Vitro to In Vivo Extrapolation (IVIVE) and how a model-based approach following routine perpetrator potential studies (i.e. CYP inhibition, CYP induction, and transporter inhibition) assessing clinical potential may eliminate the need of conducting clinical studies. Listen in as Dr. Limaye outlines a step–wise approach for bringing robustness to the prediction, including...

ADME 101: Biobank Fatty Liver Disease Tissues and Their Exploration in Microarrays

Presenter: Maciej Czerwinski, Ph.D., SEKISUI XenoTech Director of Consulting This ADME 101 discusses biobank tissue and its research applications. The Research Biobank was established to...

ADME 101: Enzyme Induction Studies

The clearance of a drug can be increased and its effectiveness or safety compromised if it is co-administered with a second drug that induces the enzyme responsible...

ADME 101: Which Hepatocyte Test System Should I Use?

Presented by Chris Bohl, Ph.D., Global Technical Support Manager This ADME 101 video provides an overview of different types of hepatocytes, their unique benefits, and...

ADME 101: Efflux and Uptake Drug Transporters

Presented by Andrew Taylor, Ph.D., Services Technical Support Manager Drug transport can be thought of as the AD&E in ADME, as transporters are responsible for absorption, distribution,...

ADME 101: Reaction Phenotyping Studies in Drug Metabolism

Presenter: Andrew Taylor, Ph.D., Services Technical Support Manager It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate...

ADME 101: Lysosomal Trapping

Presenter:  Andrew Taylor, Ph.D., Services Technical Support Manager This ADME 101 video discusses how compounds can become trapped by lysosomes, which can lead to high...

ADME 101: Guide to Subcellular Fractions and When to Use Which Test System

Presenter:  Chris Bohl, Ph.D., Global Technical Support Manager This ADME 101 video provides an overview of different types of subcellular fractions, such as microsomes, S9,...

What is DMPK and how does it fit into drug development?

Drug metabolism and pharmacokinetics (DMPK) is a core discipline in drug development that considers the biotransformation of a drug compound...


In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists

Presenter: Pallavi Limaye, Ph.D., DABT, SEKISUI XenoTech Director of Scientific Consulting with special Q&A guest, Brian Ogilvie, Ph.D., SEKISUI XenoTech Vice President of Scientific Consulting Originally scheduled to...

What is ADME and how does it fit into drug development?

The main aim of drug development is to get a compound that has a therapeutic effect into the form of...


ADME 101: Considerations & Calculations When Sending In Vitro Test Articles

Presenter: Patrick McAnulty, SEKISUI XenoTech Scientist II, Program Design This ADME 101 webinar discusses the #1 most frequently asked question that our Protocol Design team...

In Vitro Evaluation of Drug-Drug Interaction (DDI) Potential

In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...


Four ways to optimize preclinical in vitro data to mitigate risk of late-stage clinical failure

1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...


How can in vitro and in vivo studies help me understand my drug’s clearance?

Systemic clearance, denoting how much drug is cleared from a volume of blood per unit of time, is of critical...


ADME 101 FAQ: Tips & Tricks for Working with Plateable Hepatocytes

Presenter: Halee McElhaney, SEKISUI XenoTech Team Lead, Quality Control In the latest installment of ADME 101, one of our hepatocyte experts answers frequently asked questions...

ADME 101: Metabolite ID & Characterization Studies FAQ

Presenter: Mark Horrigan, SEKISUI XenoTech Principal Scientist, Program Oversight In this short, information-packed ADME 101 video, one of our study directors discusses the main frequently asked...

Timing of In Vitro Studies: Early, Thorough ADME for Your Compound’s Success

Beyond the need for evidence that a drug works, Food and Drug Administration (FDA) and other regulatory bodies around the...


How Can I Make Sure My Data Meets Regulatory Expectations?

Regulatory authorities publish updated guidance documents that share their expectations for endpoints and test systems with drug developers, but sometimes it is difficult to...


What In Vitro Metabolism and DDI Studies Do I Actually Need?

Though there is no ‘roadmap’ spelling out required studies to achieve regulatory approval for clinical entry, a drug candidate’s metabolism...


Are in vitro metabolism and DDI studies critical for an IND?

Presenter: Greg Loewen, Director of Technical Support at SEKISUI XenoTech Continuing our ADME 101 presentation series assisting researchers and industry professionals with navigating ADME, DMPK, and...

I Have My Data… Now What?

As a drug moves through the development pipeline, it undergoes a rigorous battery of safety assessments to prove it will...


ADME 101: DMPK and ADME in Drug Development

Presenter: Joanna Barbara, Ph.D., Vice President of Scientific Operations at SEKISUI XenoTech We are pleased to present SEKISUI XenoTech’s first ADME 101 series webinar, Acronyms Abound:...

The FDA has requested follow-up data… how do I fill in the gaps?

Because each new drug is unique in characteristics, such as chemical structure, mechanism of action, and physicochemical properties, there can...


How to Choose the Right Test Systems for Your DMPK Studies

Test systems for DMPK in vitro studies are part of the very foundation of our company. Our labs were borne of...

What topic would you like to hear about?

Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to

Access ADME